Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Lober

Nurse Practitioner Neptune, NJ Nurse Practitioner

NPI 1104070135 CMS profile 10440771

1945 Rte 33, Cardiac Surgery, Neptune, NJ 07753

Open in the dashboard

General payments

$5,487

374 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Lober of Neptune, NJ is reported in the CMS Open Payments database as having received $5,487 across 374 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,014 55
2024 General $815 58
2023 General $735 51
2022 General $1,300 89
2021 General $1,623 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Lober
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amy Lober were reported at $1,014. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amy Lober Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,623 $135 $40–$426 $132
2022 $1,300 $152 $48–$470 $149
2023 $735 $166 $54–$529 $160
2024 $815 $173 $55–$556 $164
2025 $1,014 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $849 67 payments
  2. AbbVie, Inc. $802 69 payments
  3. AstraZeneca Pharmaceuticals LP $668 31 payments
  4. Corcept Therapeutics $602 39 payments
  5. Amgen Inc. $382 25 payments
  6. GlaxoSmithKline, LLC. $257 18 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $213 15 payments
  8. Amarin Pharma Inc. $172 14 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $166 11 payments
  10. Merck Sharp & Dohme Corporation $129 9 payments
  11. Other $1,247 76 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,387 373 payments
  2. Gift $100 1 payment
Products named General payments · program years 2021–2025
  1. Korlym $602 39 payments
  2. Wegovy $406 32 payments
  3. VRAYLAR $372 36 payments
  4. BREZTRI $346 10 payments
  5. Otezla $310 20 payments
  6. Repatha $283 19 payments
  7. UBRELVY $278 21 payments
  8. TRELEGY ELLIPTA $257 18 payments
  9. Ozempic $241 16 payments
  10. RYBELSUS $241 16 payments
  11. Other $3,351 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record